arXiv · 2012.02103
Design aspects of COVID-19 treatment trials: Improving probability and time of favourable events
Abstract
As a reaction to the pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a multitude of clinical trials for the treatment of SARS-CoV-2 or the resulting corona disease (COVID-19) are globally at various stages from planning to completion. Although some attempts were made to standardize study designs, this was hindered by the ferocity of the pandemic and the need to set up trials quickly. We take the view that a successful treatment of COVID-19 patients (i) increases the probability of a recovery or improvement within a certain time interval, say 28 days; (ii) aims to expedite favourable events within this time frame; and (iii) does not increase mortality over this time period. On this background we discuss the choice of endpoint and its analysis. Furthermore, we consider consequences of this choice for other design aspects including sample size and power and provide some guidance on the application of adaptive designs in this particular context.
Explore related subjects
Keep this discovery
Jan Beyersmann, Tim Friede, Claudia Schmoor. 2020-11-27. Design aspects of COVID-19 treatment trials: Improving probability and time of favourable events. https://arxiv.org/abs/2012.02103
Cite the original work for its findings. Save a collection to share your selection of sources.